Renalytix Plc
NASDAQ: RNLX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- James R. McCullough
- Employees
- 102
- Headquarters
- New York City, United States
- IPO year
- 2020
- Market cap
- $22.5M
- Website
- https://renalytix.com
Loading RNLX…
Loading profile data…Frequently asked questions about RNLX
What does Renalytix Plc (RNLX) do?
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates mul...
Where does RNLX trade?
Renalytix Plc (RNLX) trades on the NASDAQ Global Market.
What sector is RNLX in?
Renalytix Plc (RNLX) operates in the Healthcare sector, specifically in the Medical - Healthcare Information Services industry.
Who is the CEO of Renalytix Plc?
James R. McCullough is the chief executive officer of Renalytix Plc (RNLX).
Where is Renalytix Plc headquartered?
Renalytix Plc is headquartered in United States.
Does RNLX pay a dividend?
Renalytix Plc (RNLX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNLX go public?
Renalytix Plc (RNLX) completed its initial public offering in 2020.
Is RNLX an ADR?
Yes — RNLX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Renalytix Plc reporting and dividends follow the underlying issuer.